Glofitamab Leads to Responses in Relapsed/Refractory LBCL

Cyrus M. Khan, MD, hematologist in the Division of Hematology and Cellular Therapy at West Penn Hospital of Allegheny Health Network, discusses the eligibility criteria of a phase 1/2 study (NCT03075696) evaluating glofitamab (RG6026) for the treatment of patients with large B-cell lymphoma (LBCL), and provides data from the expansion cohorts of the trial.

Transcription:

0:10 | It was a multicenter clinical trial across many different countries, mostly in Europe, but our center also participated. It was for all comers if they had relapsed/refractory large B-cell lymphoma. There were certain inclusion and exclusion criteria, but it was broad. We could enroll a lot of patients and if you look at the results, there were even patients post-CAR T-cell therapy that were enrolled with refractory disease, primary refractory disease, and so on and so forth. It was a broad-based clinical trial for these difficult to treat patients.

0:47 | A long-term follow-up was presented. We looked at the number of patients who achieved the response. About half of the patients achieved some form of response, about a third of the patients achieved the complete response, and the focus was on those complete responders at this meeting, which was about seven or so patients. The idea was to see what those patients did after completion of those 12 cycles and to see how they're doing or whether they remained in response or progress. About 20% of the patients had responded, a majority had relapsed, but most were still in response. It didn't matter how many treatments they'd had before and didn't matter what kind of disease they had as far as the subtype of large B-cell lymphoma is concerned. It’s certainly interesting to see that it is relatively well-tolerated. Some infections are seen longer term, but most of the patients did well and had lower rates of [cytokine release syndrome] as well as neurotoxicity.